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Abstract 
Background: HIV care programs in resource-limited settings have hitherto concentrated on antiretroviral therapy 
(ART) access, but HIV drug resistance is emerging. In a cross-sectional study of HIV-positive adults on ART for 
≥6 months enrolled into a prospective cohort in Uganda, plasma HIV RNA was measured and genotyped if ≥1000 
copies/ml. Identified Drug resistance mutations (DRMs) were interpreted using the Stanford database, 2009 WHO list 
of DRMs and the IAS 2014 update on DRMs, and examined and tabulated by ART drug classes.
Findings: Between July 2013 and August 2014, 953 individuals were enrolled, 119 (12.5%) had HIV-RNA ≥1000 
copies/ml and 110 were successfully genotyped; 74 (67.3%) were on first-line and 36 (32.7%) on second-line ART 
regimens. The predominant HIV-1 subtypes were D (34.5%), A (33.6%) and Recombinant forms (21.8%). The common-
est clinically significant major resistance mutations associated with the highest levels of reduced susceptibility or 
virological response to the relevant Nucleoside Reverse Transcriptase Inhibitor (NRTI) were; the Non-thymidine ana-
logue mutations (Non-TAMS) M184V—20.7% and K65R—8.0%; and the TAMs M41L and K70R (both 8.0%). The major 
Non-NRTI (NNRTI) mutations were K103N—19.0%, G190A—7.0% and Y181C—6.0%. A relatively nonpolymorphic 
accessory mutation A98G—12.0% was also common. Seven of the 36 patients on second line ART had major Protease 
Inhibitor (PI) associated DRMS including; V82A—7.0%, I54V, M46I and L33I (all 5.0%). Also common were the accessory 
PI mutations L10I—27%, L10V—12.0% and L10F—5.0% that either reduce PI susceptibility or increase the replication 
of viruses containing PI-resistance mutations. Of the 7 patients with major PI DRMs, five had high level resistance to 
ritonavir boosted Lopinavir and Atazanavir, with Darunavir as the only susceptible PI tested.
Conclusions: In resource-limited settings, HIV care programs that have previously concentrated on ART access, 
should now consider availing access to routine HIV viral load monitoring, targeted HIV drug resistance testing and 
availability of third-line ART regimens.
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Background
Antiretroviral therapy (ART) improves survival and qual-
ity of life of HIV-infected individuals and controls HIV 
transmission, however HIV-1 drug resistance limits the 
benefits of ART [1].
Globally, the number of HIV-positive people is increas-
ing and the numbers of new HIV infections and mortality 
due to AIDS has declined. In 2014, globally 14.9 mil-
lion (40%) people living with HIV were receiving ART, 
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of which 13.5 million were in low- and middle-income 
countries [2]. In Uganda, 750,896 (50%) HIV infected 
people were receiving ART by December 2014 [3].
Despite the progress in the rapid ART scale up, HIV 
drug resistance profiling prior to starting ART, and rou-
tine virological monitoring and drug resistance testing 
are not yet standard HIV care in resource limited settings 
as is the case in the developed world [4]. The emergence 
of HIV drug resistance may limit the sustained benefits of 
ART in settings with limited laboratory monitoring and 
drug options. Drug resistance prevalence varies widely, at 
2.8% in sub-Saharan Africa compared to 11.5% in North 
America, while in South Africa rising levels of acquired 
antiretroviral drug resistance and newly infected patients 
with resistant viruses have been reported [5, 6].
Although HIV care programs in resource limited set-
tings have hitherto concentrated on expanding ART 
access, the emergency of HIV drug resistance is a chal-
lenge. We document the antiretroviral (ARV) drug 
resistance mutations and susceptibility patterns among 
Ugandan adults on ART. We also highlight the need for 
HIV care programs in resource limited settings to avail 
access to routine virological monitoring, access to tar-
geted HIV drug resistance testing and alternative third 
line ART regimen drugs.
This was a cross-sectional study of HIV-positive adults 
(18  years and above) at enrolment into a prospective 
clinical cohort established to study the complications 
of long-term ART (CoLTART). Individuals on ART for 
6 months or more were recruited from two ART cohorts; 
the Entebbe site of the former Development of Antiret-
roviral Therapy in Africa (DART) Trial cohort estab-
lished in 2003 [7], and the former Rural Clinical Cohort 
in south western Uganda where ART was introduced 
in 2004 [8]. ART history was obtained from the former 
ART cohorts and included; dates of ART initiation and 
switches, ART regimens, baseline viral load and CD4 cell 
counts. First-line ART regimens consisted of two nucle-
oside reverse transcriptase inhibitors (NRTI) and one 
non-nucleoside reverse transcriptase inhibitor (NNRTI). 
Some participants in the DART Trial initiated ART with 
a triple nucleoside (3 NRTIs) first-line ART regimen. Sec-
ond-line ART regimens consisted of one or two NRTIs 
and a boosted protease inhibitor (PI). Individual ARVs in 
an ART regimen were substituted in the event of adverse 
drug effects, contraindications by medical conditions or 
interactions with other concurrently administered medi-
cations while complete ART switches were made in the 
event of treatment failure.
CD4 cell counts were measured with the FACSCount 
or FACSCalibur machine (Becton–Dickinson, USA). 
Plasma HIV-1 RNA was quantified using the Cobas 
Ampliprep/Cobas Taqman 48 version 2.0 HIV-1 viral 
load assay, [Roche Molecular Diagnostics (RMD), NJ, 
USA]. Samples with HIV RNA viral load of 1000 cop-
ies/mL or higher were genotyped. For ARV drug resist-
ance testing, HIV RNA was extracted using the QIAmp 
Viral RNA mini kit (Qiagen), the entire protease and 
amino terminus of the reverse transcriptase was ampli-
fied, cleaned and sequenced using the ABI 3500 machine 
(Applied Biosystems). Sequences were base-called using 
Sequencher v5.2.4 and sequence alignments performed 
using BioEdit v7.2.5 [9] and SeaView v4.0 [10]. HIV-1 
subtyping was done using SCUEAL and REGA online 
software [11], and Recombinant Identification Program 
(RIP). Drug resistance mutations (DRMs) were inter-
preted using the Stanford HIVdb Program. Assigned 
DRMs were interpreted using the 2009 WHO list for 
epidemiological surveillance of TDR alongside the lAS 
2014 Update of DRMs of HIV-1. Basic phylogenies were 
performed to determine sequence relatedness and to rule 
out contaminations. Sequences with genetic mixtures of 
wild-type and mutant sequences at amino acid sites that 
code for SDRMs were considered to be drug-resistant. 
Quality Assurance was done using the Calibrated Popula-
tion Resistance tool (CPR), Stanford and the Los Alamos 
National database (LANL dbase) for the HIV Sequence 
Quality Analysis [12]. The Laboratory is WHO HIVDR 
Region accredited.
Participants with HIV-1 RNA viral load of 1000 copies/
mL or higher, whose samples were successfully ampli-
fied and genotyped were included in this analysis. The 
socio-demographic characteristics including age and sex 
were examined and tabulated. ART data consisted of the 
type of ART regimen and duration on ART. The three 
ART regimen types were; Triple nucleoside (3 NRTIs), 
2 NRTIs with a NNRTI, and a PI-based regimen. Dura-
tion on ART was grouped into below 5 years, 5–9 years, 
and above 9  years. Drug resistance mutations to one 
antiretroviral class only (either NRTI, NNRTI or PI), two 
classes only (either NRTI and NNRTI, PI and NRTI, or 
PI and NNRTI) or three antiretroviral classes (NRTI and 
1 NNRTI and PI) were tabulated. For participants with a 
major PI DRM, we showed the resistance levels to each 
antiretroviral drug.
Findings
Out of the 953 individuals on ART for 6 or more months, 
119 (12.5%) had a viral load ≥1000 copies/ml. The five 
samples that did not amplify and the 4 with insufficient 
quantities were excluded from this analysis. Of the 110 
individuals whose samples were sequenced for drug 
resistance testing, 73 (66.4%) were females, 95 (86.4%) 
were aged 35  years and above, 89 (80.9%) had been on 
ART for 9 or more years, with 74 (67.3%) on first and 
36 (32.7%) on second-line ART regimens at enrolment. 
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Sixty-five (59.1%) had CD4 cell counts of 350 cells/ml or 
less and 67 (60.9%) had HIV RNA of 10,000 copies/ml or 
more. The predominant HIV-1 subtypes were D (34.5%), 
A (33.6%) and Recombinant forms (21.8%) (Table 1). Of 
the 110 individuals with drug resistance testing results, 
8 (7.3%) had no detectable drug resistance mutations 
(DRMs) while 102 (92.7%) had at least one detectable 
DRMs, distributed as follows: DRMs to any NRTI—92 
(83.6%), to any NNRTIs—77 (70.0%) and to any PIs—33 
(30.0%). DRMs by ART regimen line were: triple nucleo-
side—39 (35.5%), 2NRTI with an NNRTI—31 (28.2%) 
and second-line PI based regimen—33 (30.0%). Twenty-
two participants (20.0%) had DRMs to one ARV class 
only (NRTI—14, NNRTI—7 and PI—1), 60 (54.5%) par-
ticipants had dual-class DRMs (NRTI  +  NNRTI—48, 
PI  +  NRTI—10 and PI  +  NNRTI—2, while 20 (18.2%) 
had triple class DRMs (Table 2). 
In our cohort, the commonest clinically significant 
major NRTI resistance mutations associated with high-
est levels of reduced susceptibility or virological response 
were the Non-thymidine analogue mutations (Non-
TAMs): M184V—20.7% and K65R—8.0%, while M41L 
and K70R (both 8.0%) were the commonest TAMs. The 
commonest major NNRTI resistance mutations known to 
reduce susceptibility or virological response to NNRTIs 
were: K103N—19.0%, G190A—7.0% and Y181C—6.0%. 
A relatively nonpolymorphic accessory mutation A98G—
12.0% was also common. Of the 33 identified PI resistance 
mutations, 7 were major mutations and 26 minor muta-
tions. The most common major PI-resistance mutations 
associated with the highest levels of phenotypic resist-
ance were: V82A—7.0% and I54V, M46I, L33I (all 5.0%). 
The identified accessory PI resistance mutations that 
either reduce PI susceptibility or increase the replication 
of viruses containing PI-resistance mutations included: 
L10I—27.0%, L10V—12.0% and L10F—5.0% (Table 2).
Of the 7 patients with major PI DRMs, high level resist-
ance to Indinavir (IDV), Fosamprenavir (FPV), Lopinavir 
(LPV) and Nelfinavir (NFV)—to each was found among 4 
patients. Intermediate level drug resistance to Saquinavir 
(SQV) was found among 4 patients, Tipranavir (TPV) and 
IDV among 3 patients. The HIV among six of the 7 patients 
with major PI mutations were susceptible to Darunavir 
with one expressing low level resistance to this drug, and 
two expressing susceptibility to Tipranavir (Table 3).
Conclusions
We found that nearly half of our patients with virological 
failure had resistance to both NRTIs and NNRTIs, about 
a fifth had resistance to the three classes of ARVs com-
monly used in Uganda while a small proportion had no 
Drug Resistance Mutations (DRMs). NRTIs have fewer 
side effects and toxicity than NNRTIs, but drug resistance 
could diminish their efficacy. As expected in Africa, the 
predominant NRTI mutation observed was M184V [13]. 
Type 1 TAM M41L causes higher levels of phenotypic 
and clinical resistance to thymidine analogues and cross 
resistance to Abacavir, Tenofovir and Didanosine than 
Type 11 K70R. The M184V and K65R DRMs might be 
Table 1 Characteristics of participants with HIV viral loads 
≥1000 copies/ml at enrolment by ART regimen line
Missing variable data: a = 1 patient on first line ART, b = 8 patients (6 on first 
and 2 on second line ART), c = 13 patients on second line ART
Characteristic All participants 
n (%)
ART regimen line
First line ART 
n (%)
Second line ART 
n (%)
All (n, row %) 110 74 (67.3) 36 (32.7)
Study site
Entebbe 90 (81.8) 65 (87.8) 25 (69.4)
Kyamulibwa 20 (18.2) 9 (12.2) 11 (30.6)
Sex
Females 73 (66.4) 53 (71.6) 20 (55.6)
Males 37 (33.6) 21 (28.4) 16 (44.4)
Age, years
18–34 15 (13.6) 6 (8.1) 9 (25.0)
35–49 72 (65.5) 50 (67.6) 22 (61.1)
50+ 23 (20.9) 18 (24.3) 5 (13.9)
Body Mass Index (kg/m2)a
<18.5 15 (13.6) 7 (9.5) 8 (22.2)
18.5–24.9 63 (57.3) 44 (59.5) 19 (52.8)
25.0–29.9 20 (18.2) 14 (18.9) 6 (16.7)
≥30 11 (10.0) 8 (10.8) 3 (8.3)
HIV subtype
A 37 (33.6) 25 (33.8) 12 (33.3)
B 5 (4.5) 3 (4.1) 2 (5.6)
C 6 (5.5) 5 (6.8) 1 (2.8)
D 38 (34.5) 22 (29.7) 16 (44.4)
CRF01_AE 24 (21.8) 19 (25.7) 5 (13.9)
CD4 cell counts at enrolment—cells/mlb
≤350 65 (59.1) 41 (55.4) 24 (66.7)
351–500 26 (23.6) 22 (29.7) 4 (11.1)
501+ 11 (10.0) 5 (6.8) 6 (16.7)
Total duration on ART, years
0–<5 15 (13.6) 9 (12.2) 6 (16.7)
5–<9 6 (5.5) 2 (2.7) 4 (11.1)
9+ 89 (80.9) 63 (85.1) 26 (72.2)
Duration on current ART regimen, yearsc
<5 17 (15.5) 9 (12.2) 8 (22.2)
5–<9 17 (15.5) 2 (2.7) 15 (41.7)
9+ 63 (57.3) 63 (85.1) 0 (0.0)
Viral loads (copies/ml)
1000–9999 43 (39.1) 29 (39.2) 14 (38.9)
10,000+ 67 (60.9) 45 (60.8) 22 (61.1)
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due to the Tenofovir and Lamivudine ART backbone and 
the triple nucleoside regimen of Abacavir-Zidovudine-
Lamivudine that most of our patients were initiated on. 
Triple nucleoside first-line ART regimens have since been 
discontinued as they are virologically inferior to a regimen 
containing Efavirenz (NNRTI) plus two or three NRTIs 
[14]. The NNRTI mutations observed included K103N, 
G190A and Y181C which cause high level resistance to 
Nevirapine and variable resistance to Efavirenz [15].
The observed PI resistance mutations (V82A, V82F, 
V82S, M46I, M46L and I54V) are clinically significant 
because they are associated with highest levels of pheno-
typic resistance and/or strongest evidence for interfer-
ing with successful PI therapy. Among the seven patients, 
these mutations conferred high level resistance to ritonavir 
boosted Lopinavir and Atazanavir, which are the readily 
available PIs for second-line ART regimens in our setting. 
Darunavir, the only susceptible PI tested is still expensive 
and unavailable in public ART centers in Uganda where 
PIs are reserved for second-line ART regimens. The 
emergence of HIV drug resistance is inevitable, owing to 
the high replication and mutation rates of HIV and ART 
being a life-long treatment. Therefore, as more people are 
switched to second-line ART, cases of second-line drug 
failure will increase and necessitate access to third-line or 
salvage regimens. In Uganda, routine viral load monitor-
ing is not yet standard care, making early identification 
of treatment failures to prevent transmission of DRMs 
impossible. Uganda is yet to recommend HIV genotyping 
prior to ART initiation, therefore diagnosing transmitted 
Table 2 Drug resistance mutations (DRMs) of  participants tested for  drug resistance among  those with  HIV viral loads 
≥1000 copies/ml at enrolment, by ARV class
TAMs thymidine analogue mutations
1 These are row percentages of participants with major PI mutations in each category with amplified drug resistance tests
2 Denominator is all mutations to NRTI (n = 352), NNRTI (n = 144) or PI (n = 59)
3 PI DRMs include 7 with a major and 26 with only minor PI DRMs
4 Only major PI mutations are shown for HIV subtypes
Drug resistance  
mutation(s)
Proportion with amplified  
drug resistance tests, n (%)
Proportion with major  
PI mutations, n (%)1 
Most common mutations2
All 110 7 (6.4)
No mutation detected 8 (7.3)
At least one detected (NRTI, NNRTI, PI) 102 (92.7) 7 (6.9)
Any NRTI 92 (83.6) 6 (6.5) Non-TAMs: M184V (20.7%), K65R 
(8.0%) TAMs: M41L (8.0%), K70R 
(8.0%)
Any NNRTI 77 (70.0) 4 (5.2) K103N (19.0%), G190A (7.0%), Y181C 
(6.0%)
Any PI3 33 (30.0) 7 (21.2) Major: V82A (7.0%) and I54V, M46I, 
L33I (all 5.0%) Accessory: L10I 
(27.0%), L10V (12.0%), L10F(5.0%)
Mutation to 1 ARV class only (n = 22)
NRTI 14 (12.7) 0 (0.0)
NNRTI 7 (6.4) 0 (0.0)
PI 1 (0.9) 0 (0.0)
Mutation to 2 ARV classes only (n = 60)
NRTI + NNRTI 48 (43.6) 0 (0.0)
PI + NRTI 10 (9.1) 3 (30.0)
PI + NNRTI 2 (1.8) 1 (50.0)
Mutations to 3 ARV classes (n = 20)4 20 (18.2) 3 (15.0)
HIV subtype
A 37 (33.6) 3 (8.1) V82A/S, I54V/U, M46I/L, K43T, L10F, 
L89V, L24IL
B 5 (4.5) 0 (0.0)
C 6 (5.5) 0 (0.0)
D 38 (34.5) 4 (10.5) V82A/V/F, I54IV, I54V, M46I, L33F, L10I, 
L10F, L24I, K20T, A71T, Q58E, I47V
CRF01_AE 24 (21.8) 0 (0.0)
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HIV drug resistance is impossible. The strength of our 
study is the long duration on ART among our participants. 
A source of selection bias might be that some patients with 
virological failure might have died before enrolment. We 
also had limited information on confounders like adher-
ence so our findings may not be generalizable. In conclu-
sion, HIV drug resistance is a major challenge for HIV care 
programs in resource limited settings that have hitherto 
concentrated on increasing ART access. Therefore, ART 
programs in these settings should avail routine HIV viral 
load monitoring for prompt detection of virological fail-
ures, targeted HIV drug resistance testing to detect HIV 
drug resistance among ART failure as well as access to 
third-line ARV drugs like Darunavir.
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